Product Description
Tyzivumab is a first-in-class monoclonal antibody designed and engineered to neutralize Zika virus by binding to a specific quaternary epitope of the envelope (E) protein on virus surface. (Sourced from: https://www.tychan.com)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tychan Pte Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Zika Virus Infection
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500106333 |
ChiCTR2500106333 | N/A |
Not yet recruiting |
Oncology Unspecified |
2026-06-30 |
|||
NCT03776695 |
ZKT-002 | P1 |
Withdrawn |
Zika Virus Infection |
2022-01-05 |
50% |
2022-03-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03443830 |
ZKT-001 | P1 |
Completed |
Zika Virus Infection |
2018-09-12 |
50% |
2023-02-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/17/2021 |
News Article |
Scientific Journal Antiviral Research Publishes Study Demonstrating Benefits of Tychan's Antibody Discovery Technology Platform |
|
12/11/2020 |
News Article |
Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027 |